JK184 is a potent and cell-permeable inhibitor of hedgehog (Hh) signaling downstream of Smo, identified by a cell-based Hh pathway reporter screening. JK184 was found to inhibit Adh7 (IC₅₀ ~210 nM), the class IV alcohol dehydrogenase as well as act as a microtubule depolymerizing agent in vitro. JK184 inhibits Hh agonit-induced Gli transcriptional activity (IC₅₀ ~30 nM) as well as Gli1 and Ptc1 mRNA expression in a dose-dependent manner in 10T1/2 cells. It shows antiproliferative activity in a range of cancer cell lines (IC₅₀ ~ 3 - 21 nM), and inhibits the growth of two xenografted tumors in mice in vivo.

How to Use: 

• In vitro: JK184 was suggested to use at 1-5 µM concentration in vitro and in the cellular assays.
• In vivo: JK184 was dosed orally 0.2 mg/mouse once per day.  

Reference:

• 1. Lee J, et al. A small-molecule antagonist of the hedgehog signaling pathway. (2007) Chembiochem      8(16):1916-9.
• 2. Cupido T, et al. The imidazopyridine derivative JK184 reveals dual roles for microtubules in Hedgehog signaling. (2009)Angew Chem Int Ed Engl.      48(13):2321-4.

Products are for research use only. Not for human use.